SANA
HealthcareSana Biotechnology, Inc.
$4.06
$-0.13 (-3.10%)
Jan 5, 2026
Price History (1Y)
Analysis
Sana Biotechnology, Inc. is a healthcare company operating in the biotechnology industry within the sector of Healthcare. As of the available facts, the company has a market capitalization of $1.08B and employs 194 individuals. The financial health of Sana Biotechnology indicates that the company has experienced significant losses, with a net income of -$234,410,000 (TTM) and an EBITDA of -$176,700,000. The company's gross margin, operating margin, and profit margin are all at 0.0%. Returns on equity and assets are also negative, at -96.1% and -23.9%, respectively. The balance sheet shows that Sana Biotechnology has a debt-to-equity ratio of 45.95 and cash reserves of $153.05M. The valuation context for Sana Biotechnology is characterized by a forward P/E ratio of -7.17, which suggests that the company's stock price may be undervalued or overvalued in comparison to its earnings. The debt-to-equity ratio and negative returns on equity and assets provide further context regarding the company's financial situation.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Visit website →Key Statistics
- Market Cap
- $1.08B
- P/E Ratio
- N/A
- 52-Week High
- $7.30
- 52-Week Low
- $1.26
- Avg Volume
- 5.30M
- Beta
- 1.97
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 194